The Effects of OMACOR on the LDL Sub-Fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia.

Trial Profile

The Effects of OMACOR on the LDL Sub-Fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Hyperlipoproteinaemia type IIb
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
    • 07 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 07 Aug 2009 Actual initiation date (1 Jul 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top